Results 51 to 60 of about 40,182 (268)

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

open access: yesJournal of Translational Medicine
Background Delta-like ligand 3 (DLL3) is highly expressed on the cell surface of small cell lung cancer (SCLC), one of the most lethal malignancies, but minimally or not in normal tissues, making it an attractive target for SCLC.
Shengchao Lin   +6 more
doaj   +1 more source

A dual method for polar cuts in disjoint bilinear programming

open access: yesCroatian Operational Research Review
As one branch of deterministic approaches to disjoint bilinear programming, cutting plane methods are renowned for its ability to systematically reduce the search space by adding cutting planes that are able to cut off regions deemed infeasible or ...
Xiaosong Ding, Jun Ma, Xi Chen, Chao Liu
doaj   +1 more source

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi‐Center Phase‐III Randomized Clinical Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier   +11 more
wiley   +1 more source

Groups of Dualities [PDF]

open access: yesTransactions of the American Mathematical Society, 1993
For arbitrary categories A \mathcal {A} and
Dimov, Georgi D., Tholen, Walter
openaire   +2 more sources

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

open access: yesJournal of Translational Medicine
Background HER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Multiple HER3-targeting antibodies and antibody–drug conjugates (ADCs) were developed for the solid tumor treatment ...
Xi Li   +8 more
doaj   +1 more source

The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi   +7 more
wiley   +1 more source

The Implementation Duality [PDF]

open access: yesSSRN Electronic Journal, 2015
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Nöldeke, Georg, Samuelson, Larry
openaire   +5 more sources

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas   +3 more
wiley   +1 more source

Change in Mental Health and Resilience in Childhood Cancer Survivors After Attending a Person‐Centred State‐of‐the‐Art Late Effects Clinic—on Behalf of the PanCareFollowUp Consortium

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Person‐centred follow‐up care based on evidence‐based clinical practice guidelines and providing individualised information should help to inform and reassure survivors about their medical and psychosocial situation and provide treatment and support where needed.
Gisela Michel   +36 more
wiley   +1 more source

Home - About - Disclaimer - Privacy